La catena delle opzioni mostra i dati chiave delle opzioni azionarie di HilleVax a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per HilleVax..

HilleVax (NASDAQ:HLVX) Azioni, Catena delle Opzioni

HilleVax

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

HilleVax Inc

Trading Ideas

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Holdings Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 123.5%

<p>Cryptocurrency markets are trading relatively flat, with Dogecoin seeing rising momentum.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$90,765.13</td>
<td>+0.7%</td>
</tr>
<tr>
<td><strong>Ethereum</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,133.91</td>
<td>+0.9%</td>
</tr>
<tr>
<td><strong>Solana</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$236.42</td>
<td>-0.2%</td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3681</td>
<td>+1.9%</td>
</tr>
<tr>
<td><strong>Shiba Inu </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002437&nbsp;</td>
<td>-2.6%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 16.2% and daily active addresses falling by 12.4%. Transactions greater than $100,000 are down from 9,207 to 8,261 in a single day. Exchanges netflows are down by 38.3%.</li>
<li>Coinglass data reports 124,438 traders were liquidated for $349.60 million.</li>
<li>Billionaire Paul Tudor hedge fund <a href="https://x.com/WatcherGuru/status/1858594624362643594">holds</a> $230 million worth of BlackRock&#8217;s spot Bitcoin ETF.</li>
</ul>
<p><strong>Notable Developments:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42042019/bitcoin-buyer-spree-microstrategy-acquires-4-6b-in-btc-metaplanet-issues-11-4m-in-bonds-to-fund-purchases">Bitcoin Buyer Spree: MicroStrategy Acquires $4.6B In BTC, Metaplanet Issues $11.4M In Bonds To Fund Purchases</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42033429/exclusive-binance-ceo-richard-teng-says-2025-will-outshine-2024-for-crypto">EXCLUSIVE: Binance CEO Richard Teng Says 2025 Will Outshine 2024 For Crypto</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42036066/tidus-wallet-brings-wormhole-integration-for-ethereum-solana-transfers">Tidus Wallet Brings Wormhole Integration For Ethereum-Solana Transfers</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42028720/gita-gopinath-of-imf-alarmed-by-crypto-and-ai-energy-use-says-share-expected-to-match-japans-current-power-consumption-in-just-3-years">Gita Gopinath Of IMF Alarmed By Crypto And AI Energy Use, Says Share Expected To Match Japan&#8217;s Current Power Consumption In Just 3 Years</a></li>
<li><a href="https://www.benzinga.com/24/11/42030758/man-who-facilitated-bitcoin-laundering-worth-over-300m-awarded-a-three-year-jail-sentence">Man Who Facilitated Bitcoin Laundering Worth Over $300M Sentenced To 3 Years In Prison</a></li>
</ul>
<p><strong>Top Gainers:</strong></p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Tezos</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xtz/usd">XTZ</a>)</td>
<td>&nbsp;$1.21</td>
<td>+53.3%</td>
</tr>
<tr>
<td><strong>Hedera</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>)</td>
<td>&nbsp;$0.1241</td>
<td>+41%</td>
</tr>
<tr>
<td><strong>Theta Network</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/theta/usd">THETA</a>)</td>
<td>&nbsp;$1.72</td>
<td>+19%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>With Bitcoin prices trading relatively flat, Altcoin Sherpa sees Bitcoin continuing to have &#8220;mini consolidations.&#8221;  He <a href="https://x.com/AltcoinSherpa/status/1858534136836661685">believes</a> Bitcoin will continue without much pullback as it has consolidated for months. It is now "time to go."</p>
<p>CryptoCon predicts Bitcoin's monthly RSI bull run has arrived with two major tops remaining.&nbsp; The trader says there is lots of room to grow.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">The <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> Monthly RSI bull run is here, with two major tops to go.<br /><br />March 2024 at first glance may look like a topping point in overbought territory, but it&#39;s a mirror of 2017&#8230; resistance at All Time Highs.<br /><br />This indicator is simple and effective. <br /><br />What&#39;s the point here?… <a href="https://t.co/l4cb7jGY5G">pic.twitter.com/l4cb7jGY5G</a></p>
<p>&mdash; CryptoCon (@CryptoCon_) <a href="https://twitter.com/CryptoCon_/status/1858575776410386933?ref_src=twsrc%5Etfw">November 18, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Crypto trader Blackwidow predicts if Bitcoin cannot break and hold $91,000, there is a possibility of "a cool off before continuation end of the year or early 2025." He <a href="https://x.com/blackwidowbtc/status/1858593478302663129">sees</a> a mania phase in 2025.</p>
<p>Crypto chart analyst Ali Martinez explained that Bitcoin surged 26% after breaking its all-time high of $19,700 in 2020. </p>
<p>It consolidated for a week and then spiked to $40,000. He is predicting a repeat in history as BTC has risen 28% since surpassing its previous ATH and has been consolidating for six days.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">In 2020, after <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> broke its previous all-time high of $19,700, it surged 26%, consolidated for a week, then jumped to $40,000.<br /><br />Fast forward to today: <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> has risen 28% after surpassing its previous ATH and has been consolidating for the past six days. History might be… <a href="https://t.co/fuKygwla6x">pic.twitter.com/fuKygwla6x</a></p>
<p>&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1858484914519248907?ref_src=twsrc%5Etfw">November 18, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>What&#8217;s Next</strong>: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42038909/bitcoin-to-100000-seems-around-the-corner-bulls-are-on-the-right-side-of-historybernstein">Bitcoin To $100,000 &#8216;Seems Around The Corner,&#8217; Bulls Are &#8216;On The Right Side Of History&#8217;—Bernstein</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$DOGE

$ETH

$HBAR

$SHIB

$SOL

$THETA

$XTZ

Bitcoin, Ethereum Open The Week Relatively Flat, Dogecoin Moves Higher, Trader Marks $91,000 As Key BTC Level To Prevent 'Cool Off'

Bakkt Holdings Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 86.2%

<p><strong>IonQ Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares are trading lower Monday, pulling back after rallying in recent weeks. Here&#8217;s what <a href="https://www.benzinga.com/quote/IONQ/news">you need to know.</a></p>
<p><strong>What To Know:</strong> IonQ shares are up more than 60% since the start of the month, and have more than doubled since the start of the year. The stock opened lower Monday and quickly traded down from around $28.50 to around $22.30 before bouncing and leveling off between $24 and $25 per share.</p>
<p>IonQ shares really took off after the company reported quarterly financials near the start of November. IonQ reported <a href="https://www.benzinga.com/news/earnings/24/11/41817317/ionq-stock-is-soaring-thursday-whats-going-on">third-quarter revenue</a> of $12.4 million, beating analyst expectations of $10.56 million. The company posted a loss of 24 cents per share, versus an expected loss of 21 cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. </p>
<p>The company&#8217;s quarterly report was accompanied by a series of partnerships and contract announcements, including a $54.5 million contract with the U.S. Air Force Research Lab and the creation of a new quantum application development center in collaboration with AstraZeneca.</p>
<p>Following the report, several analysts raised <a href="https://www.benzinga.com/analyst-stock-ratings">price targets</a> on IonQ, which helped shares sustain positive momentum throughout the week. The company also announced that it was <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41945075/ionq-stock-is-trading-higher-today-whats-going-on">issued five new U.S. patents</a>, covering advancements in quantum computing across multiple industries and applications.</p>
<p>IonQ shares briefly saw some buyers come into the name in afternoon trading on Monday after the company demonstrated a hybrid quantum computing workflow using the <strong>NVIDIA Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CUDA-Q platform and its quantum hardware.</p>
<p>IonQ and Nvidia presented the application workflow together at SC24. The companies believe the new approaches have potential relevance in many chemistry-focused commercial applications.</p>
<p>&#8220;IonQ is building on its approach of accelerating AI, scientific compute, and other supercomputing workloads with quantum hardware – enabling entirely new ways to approach previously unsolvable problems,&#8221; said <strong>Dean Kassmann</strong>, SVP of Engineering &amp; Technology at IonQ. </p>
<p>&#8220;Today&#8217;s molecular modeling demonstration illustrates why CUDA-Q is a great platform for achieving seamless integration and top-tier performance with our leading quantum hardware.&#8221;</p>
<p><strong>IonQ Price Action: </strong>IonQ shares were down 15.4% at $24.66 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1-1024x543.png" alt="" class="wp-image-653689" style="width:450px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1.png 1165w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/fda/24/11/42046777/ispire-and-ike-tech-advance-fda-backed-age-verification-tech-to-curb-youth-vaping">Ispire And IKE Tech Advance FDA-Backed Age Verification Tech To Curb Youth Vaping</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Movers

IONQ

NVDA

What's Going On With IonQ Stock Today?

<p><i>- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions -</i></p>
<p>SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR)&nbsp;conference, being held in Washington, D.C. from November 14-19, 2024.</p>
<p>NKTR-422 is a novel modified&nbsp;hematopoietic colony stimulating factor (CSF) protein engineered to selectively modulate resolution processes of inflammation by targeting the expansion, reprograming and activation of anti-inflammatory tissue resident macrophages.</p>
<p>Currently approved inflammatory disease therapies are not designed to achieve inflammation resolution or tissue repair, which are both required for remission.1 Nektar has identified a CSF-1R agonist with a differentiated pharmacokinetic (PK)/pharmacodynamic (PD) profile compared to the native CSF-1 cytokine. Reduced clearance enables sustained PD activity from a single dose, unlike historical multiple dose per day necessary regimens of recombinant human CSF-1 administration. This CSF-1R agonist, NKTR-422, demonstrated inflammation resolution and tissue repair markers induction in tissue resident macrophages without induction of monocytosis and enhanced the efficacy of inflammatory cytokine blockade in rodent models.</p>


Biotech

General

NKTR

Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology  Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflammatory Conditions

<p>Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 7% of traders were bullish, while 76% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $855,036, and 3 were calls, valued at $419,310.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $62.5 to $85.0 for Insmed over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Insmed stands at 2968.25, with a total volume reaching 15,604.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Insmed, situated within the strike price corridor from $62.5 to $85.0, throughout the last 30 days.</p>
<h3>Insmed Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731961828_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.2</td>
<td>$0.75</td>
<td>$1.2</td>
<td>$85.00</td>
<td>$360.0K</td>
<td>7.1K</td>
<td>3.0K</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.1</td>
<td>$3.8</td>
<td>$4.06</td>
<td>$62.50</td>
<td>$150.3K</td>
<td>504</td>
<td>2.3K</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.5</td>
<td>$3.4</td>
<td>$3.9</td>
<td>$62.50</td>
<td>$142.3K</td>
<td>504</td>
<td>365</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$62.50</td>
<td>$138.4K</td>
<td>504</td>
<td>1.5K</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$62.50</td>
<td>$123.2K</td>
<td>504</td>
<td>746</td>
</tr>
</tbody>
</table>
</p>
<h3>About Insmed</h3>
<p>Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.</p>
<p>After a thorough review of the options trading surrounding Insmed, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Insmed Standing Right Now?</h3>
<ul>
<li>With a trading volume of 891,951, the price of INSM is down by -0.03%, reaching $66.27.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 94 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Insmed</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $97.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $105.<br />
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $90.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Insmed options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

INSM

Insmed's Options: A Look at What the Big Money is Thinking

Bakkt Holdings Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 65.2%

<p>Financial giants have made a conspicuous bearish move on Trump Media &amp; Technology. Our analysis of options history for Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) revealed 58 unusual trades.</p>
<p>Delving into the details, we found 39% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 22 were puts, with a value of $1,154,360, and 36 were calls, valued at $3,115,636.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $24.0 to $115.0 for Trump Media &amp; Technology over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Trump Media &amp; Technology's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Trump Media &amp; Technology's substantial trades, within a strike price spectrum from $24.0 to $115.0 over the preceding 30 days.</p>
<h3>Trump Media &amp; Technology Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731961823_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.5</td>
<td>$11.65</td>
<td>$12.5</td>
<td>$25.00</td>
<td>$249.8K</td>
<td>416</td>
<td align="right">200</td>
</tr>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$13.1</td>
<td>$11.55</td>
<td>$12.35</td>
<td>$25.00</td>
<td>$247.0K</td>
<td>416</td>
<td align="right">400</td>
</tr>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$12.1</td>
<td>$12.1</td>
<td>$25.00</td>
<td>$242.0K</td>
<td>416</td>
<td align="right">600</td>
</tr>
<tr>
<td>DJT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$10.85</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$25.00</td>
<td>$156.0K</td>
<td>455</td>
<td align="right">300</td>
</tr>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.35</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$50.00</td>
<td>$141.0K</td>
<td>1.2K</td>
<td align="right">835</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trump Media &amp; Technology</h3>
<p>Trump Media &amp; Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest global conversation without discriminating against political ideology.</p>
<p>In light of the recent options history for Trump Media &amp; Technology, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Trump Media &amp; Technology</h3>
<ul>
<li>With a volume of 12,214,290, the price of DJT is down -2.48% at $27.4. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Trump Media &amp; Technology with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Decoding Trump Media & Technology's Options Activity: What's the Big Picture?

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Vertex Pharmaceuticals</strong>.</p>
<p>Looking at options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $266,785 and 3, calls, for a total amount of $162,840.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $420.0 to $550.0 for Vertex Pharmaceuticals during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $420.0 to $550.0 in the last 30 days. </p>
<h3>Vertex Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731961818_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$15.8</td>
<td>$14.6</td>
<td>$15.0</td>
<td>$450.00</td>
<td>$99.0K</td>
<td align="right">500</td>
<td align="right">66</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$46.8</td>
<td>$41.8</td>
<td>$44.0</td>
<td>$440.00</td>
<td>$88.0K</td>
<td align="right">439</td>
<td align="right">20</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.3</td>
<td>$13.6</td>
<td>$15.0</td>
<td>$450.00</td>
<td>$51.0K</td>
<td align="right">500</td>
<td align="right">100</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$50.9</td>
<td>$44.8</td>
<td>$46.02</td>
<td>$420.00</td>
<td>$46.0K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.95</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$550.00</td>
<td>$40.2K</td>
<td align="right">69</td>
<td align="right">152</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vertex Pharmaceuticals</h3>
<p>Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.</p>
<p>Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.</p>
<h3>Vertex Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a volume of 565,702, the price of VRTX is up 0.06% at $466.0. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Expert Opinions on Vertex Pharmaceuticals</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $492.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Vertex Pharmaceuticals, targeting a price of $486.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Vertex Pharmaceuticals with a target price of $503.<br />
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Vertex Pharmaceuticals, targeting a price of $540.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $480.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $451. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


VRTX

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics

WIIM

FANG

SHEL

Shares of energy and oil stocks are trading higher amid a rise in the price of oil, which gained on Russia-Ukraine tensions and a Norway oilfield shutdown.

Bakkt Holdings shares are trading higher following a report suggesting Trump Media and Technology Group is in talks to buy the company.

<p><a href="https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-18-2024/card/exclusive-trump-to-meet-privately-with-coinbase-ceo-brian-armstrong-DDkgF0xW1BW242rVeuqx?page=1" title="https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-18-2024/card/exclusive-trump-to-meet-privately-with-coinbase-ceo-brian-armstrong-DDkgF0xW1BW242rVeuqx?page=1">https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-18-2024/card/exclusive-trump-to-meet-privately-with-coinbase-ceo-brian-armstrong-DDkgF0xW1BW242rVeuqx?page=1</a></p>


COIN

'Coinbase Doled Out More Than $100M To Political Action Committees Before Election; President Trump To Meet Privately With Coinbase CEO Brian Armstrong' - WSJ

Bakkt Holdings Shares Resume Trade

Trump Media & Technology Group shares are trading higher following a report suggesting the company is in talks to acquire a crypto trading venue.

<p><i>– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 –</i></p>
<p><i>– Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 –</i></p>
<p><i>– Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% –</i></p>
<p><i>– Safety results comparable to placebo</i> <i>–</i></p>
<p>NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced additional results from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia ("HeFH"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The data were presented today in an oral late-breaker presentation at the American Heart Association (AHA) Scientific Sessions.</p>


NAMS

NewAmsterdam Pharma Presents Additional Data From Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia At AHA Scientific Sessions 2024; Met Primary Endpoint With LDL-C Mean Reduction Versus Placebo Of 36.3% At Day 84 And 41.5% At Day 365

Bakkt Holdings Shares Halted On Circuit Breaker To The Upside, Stock Now Up 12.8%

<p><a href="https://www.ft.com/content/d7f921d5-3668-4b6b-a98d-2681ad73610f">https://www.ft.com/content/d7f921d5-3668-4b6b-a98d-2681ad73610f</a><br /><br />Donald Trump's social media company is in advanced talks to buy Bakkt, a cryptocurrency trading venue owned by Intercontinental Exchange, as it pushes to expand beyond online conversation. The US president-elect's Trump Media and Technology Group, in which he has pledged to retain his 53 per cent stake, is closing in on an all-share purchase of Bakkt, said two people with knowledge of the talks. The valuation under discussion was not immediately clear but Bakkt's market capitalisation stood at just over $150mn on Monday. TMTG, which operates Truth Social, has become one of the most actively traded US stocks since Trump's election victory as retail investors try to profit on its often-volatile trading moves. Although it has reported just $2.6mn in revenues this year, TMTG has a $6bn equity valuation, giving its management a valuable currency with which to buy other companies. A successful deal would deepen Trump's move into the cryptocurrency market after he began promoting a new crypto venture set up by longtime business partners, World Liberty Financial, from which he stands to earn significant fees. Crypto markets have also soared following his election victory, with bitcoin up more than 30 per cent on speculation that his administration would enact favourable legislation for the industry. Bakkt, which has struggled for profitability since its launch, was created by ICE, and the owner of the New York Stock Exchange still holds a 55 per cent economic interest in it. Bakkt's first chief executive was Kelly Loeffler, a former head of marketing at ICE and a Republican ex-senator for Georgia during Trump's first presidency. She is co-chair of the committee organising his inauguration in January. She is also married to Jeff Sprecher, ICE's founder, chair and chief executive. ICE and Bakkt declined to comment. TMTG did not immediately respond to a request for comment.</p>


'Donald Trump's Social Media Group In Talks To Buy Crypto Trading Venue; Truth Social Owner Is Close To An All-Share Takeover Of Intercontinental Exchange's Bakkt' - Financial Times

Insider Trades

BorgWarner Form4 Filing Shows VP Stefan Demmerle Sold 21,500 Shares At An Average Price Of $34.79/Share

<p>Financial giants have made a conspicuous bullish move on PDD Holdings. Our analysis of options history for PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) revealed 87 unusual trades.</p>
<p>Delving into the details, we found 44% of traders were bullish, while 39% showed bearish tendencies. Out of all the trades we spotted, 27 were puts, with a value of $1,964,219, and 60 were calls, valued at $8,300,647.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $230.0 for PDD Holdings over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for PDD Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across PDD Holdings's significant trades, within a strike price range of $100.0 to $230.0, over the past month.</p>
<h3>PDD Holdings Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960931_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.45</td>
<td>$7.9</td>
<td>$8.31</td>
<td>$115.00</td>
<td>$2.0M</td>
<td>4.7K</td>
<td>5.0K</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.15</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$115.00</td>
<td>$2.0M</td>
<td>4.7K</td>
<td>2.5K</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$28.05</td>
<td>$27.75</td>
<td>$27.8</td>
<td>$144.00</td>
<td>$247.4K</td>
<td>0</td>
<td>139</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$38.7</td>
<td>$38.45</td>
<td>$38.45</td>
<td>$155.00</td>
<td>$192.2K</td>
<td>1.0K</td>
<td>50</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.3</td>
<td>$120.00</td>
<td>$184.5K</td>
<td>4.2K</td>
<td>654</td>
</tr>
</tbody>
</table>
</p>
<h3>About PDD Holdings</h3>
<p>PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. PDD aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.</p>
<p>Following our analysis of the options activities associated with PDD Holdings, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of PDD Holdings</h3>
<ul>
<li>Trading volume stands at 6,199,920, with PDD's price up by 3.47%, positioned at $117.96.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 3 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for PDD Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Citigourp Global Markets 2% Protected Notes Linked To The Djia

Spotlight on PDD Holdings: Analyzing the Surge in Options Activity

<p>Benzinga's options scanner just detected over 30 options trades for <strong>Freeport-McMoRan</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) summing a total amount of $2,124,128.</p>
<p>At the same time, our algo caught 7 for a total amount of 381,224.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $33.0 and $55.0 for Freeport-McMoRan, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Freeport-McMoRan stands at 3474.58, with a total volume reaching 28,080.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Freeport-McMoRan, situated within the strike price corridor from $33.0 to $55.0, throughout the last 30 days.</p>
<h3>Freeport-McMoRan 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960926_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$3.94</td>
<td>$45.00</td>
<td>$338.1K</td>
<td>351</td>
<td>876</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.62</td>
<td>$1.61</td>
<td>$1.62</td>
<td>$46.00</td>
<td>$157.9K</td>
<td>4.0K</td>
<td>2.2K</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.36</td>
<td>$1.31</td>
<td>$1.32</td>
<td>$42.00</td>
<td>$132.0K</td>
<td>8.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.8</td>
<td>$1.78</td>
<td>$1.79</td>
<td>$44.00</td>
<td>$118.2K</td>
<td>3.6K</td>
<td>745</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.15</td>
<td>$45.00</td>
<td>$108.0K</td>
<td>3.7K</td>
<td>577</td>
</tr>
</tbody>
</table>
</p>
<h3>About Freeport-McMoRan</h3>
<p>Freeport-McMoRan Inc is an international mining company. It has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines. Its reportable segments include the Morenci, Cerro Verde and Grasberg (Indonesia mining) copper mines, the Rod &amp; Refining operations and Atlantic Copper Smelting and Refining. It derives key revenue from the sale of Copper.</p>
<p>Following our analysis of the options activities associated with Freeport-McMoRan, we pivot to a closer look at the company's own performance.</p>
<h3>Freeport-McMoRan's Current Market Status</h3>
<ul>
<li>With a trading volume of 7,082,008, the price of FCX is up by 1.81%, reaching $43.48.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 65 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Freeport-McMoRan</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $54.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Freeport-McMoRan, targeting a price of $52.<br />
&#x2A; An analyst from Raymond James persists with their Outperform rating on Freeport-McMoRan, maintaining a target price of $57. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Freeport-McMoRan, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Spotlight on Freeport-McMoRan: Analyzing the Surge in Options Activity

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Warning: HLVX is at high risk of performing badly

As of September 30, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $189.3 million and $303.5...

HilleVax reports Q3 EPS (52c), consensus (42c)

HilleVax GAAP EPS of -$0.52 misses by $0.10

HilleVax, Inc ( ($HLVX) ) has released its Q3 earnings. Here is a breakdown of the information HilleVax, Inc presented to its investors. HilleVax, ...

HilleVax Reports Q3 Financial Results Amid Strategic Planning

Leerink Partners analyst David Risinger maintained a Hold rating on HilleVax, Inc (HLVX – Research Report) on November 7 and set a price target of ...

Cautious Hold Rating on HilleVax, Inc: Balancing Strong Cash Reserves with Strategic Uncertainty

ABUS

ALPMF

ALPMY

ANTX

ATHA

BAYRY

BAYZF

BBIO

BMRN

CDTX

CRBU

CVAC

FGEN

GLYC

HLVX

IBRX

INAB

LXRX

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

VIRX

Legal

Press Releases

HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX

HilleVax Announces Reduction in Force

Earnings

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Comments

HilleVax

HilleVax (HLVX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO